Compare AMCI & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMCI | INO |
|---|---|---|
| Founded | 2021 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.5M | 100.4M |
| IPO Year | 2022 | 1999 |
| Metric | AMCI | INO |
|---|---|---|
| Price | $4.74 | $1.08 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | 151.1K | ★ 4.7M |
| Earning Date | 04-20-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.18 |
| EPS | ★ 0.01 | N/A |
| Revenue | $5,980,847.00 | ★ $42,220,086.00 |
| Revenue This Year | N/A | $20,156.19 |
| Revenue Next Year | N/A | $421.95 |
| P/E Ratio | $481.00 | ★ N/A |
| Revenue Growth | N/A | ★ 19.37 |
| 52 Week Low | $3.60 | $0.56 |
| 52 Week High | $15.75 | $2.86 |
| Indicator | AMCI | INO |
|---|---|---|
| Relative Strength Index (RSI) | 49.03 | 61.32 |
| Support Level | $4.09 | $1.03 |
| Resistance Level | $5.81 | $1.24 |
| Average True Range (ATR) | 0.51 | 0.08 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 32.58 | 95.25 |
AMC Robotics Corp is a technology solutions company that offers AI-powered smart security and robotics solutions. It currently sells smart hardware products designed for residential and commercial use, including smart cameras, driving recorders, action cameras, and Retina K cameras, which are marketed under the YI brand. AMC Robotics is also engaged in developing additional hardware products and technology capabilities, including IoT-enabled devices, AI-based features, wearable devices, and AI robotics. Using its technological capabilities, the company is developing robotic dogs, robotic arms, and robotic unloading systems, offering smart solutions for the logistics and warehousing sectors. It has two primary operating segments: North America, which generates maximum revenue, and Europe.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.